We look back on a very intense and challenging 2020. Although the Covid 19 pandemic has delayed and complicated the funding, implementation, and continuation of EB research projects, clinical research, and clinical trials worldwide, we see positive developments. 

Never before have there been so many phase 3 clinical trials, and the first phase 3 trial was completed successfully. Our goal – new therapies and a cure for people with EB – seems achievable in the future, even if we know that it still takes time, more funding, and international solidarity. 

EB-ResNet will continue to provide funding for EB research worldwide and drive its clinical translation.

Thank you for the excellent cooperation and your commitment 2020.

Thank you for being part of EB-ResNet.

We wish you and your loved ones Merry Christmas and a Happy New Year!

Stay safe and healthy.

Your EB-ResNet Team

Gaston, Clare, Katrin & Sandra